Amit Mahipal

9.4k total citations · 2 hit papers
266 papers, 4.4k citations indexed

About

Amit Mahipal is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Amit Mahipal has authored 266 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 168 papers in Oncology, 110 papers in Surgery and 76 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Amit Mahipal's work include Cholangiocarcinoma and Gallbladder Cancer Studies (78 papers), Pancreatic and Hepatic Oncology Research (77 papers) and Cancer Genomics and Diagnostics (46 papers). Amit Mahipal is often cited by papers focused on Cholangiocarcinoma and Gallbladder Cancer Studies (78 papers), Pancreatic and Hepatic Oncology Research (77 papers) and Cancer Genomics and Diagnostics (46 papers). Amit Mahipal collaborates with scholars based in United States, Spain and France. Amit Mahipal's co-authors include Sri Harsha Tella, Anuhya Kommalapati, Richard D. Kim, Sakti Chakrabarti, Mokenge P. Malafa, Mitesh J. Borad, Shilpa Gupta, Zhaohui Jin, Robert R. McWilliams and Rory L. Smoot and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Amit Mahipal

242 papers receiving 4.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract Cancer

2020 306 citations Amit Mahipal et al. profile →
Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer

2019 284 citations Mark J. Truty, Michael L. Kendrick et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amit Mahipal United States	34	2.6k	1.6k	1.3k	1.1k	781	266	4.4k
Benjamin Tan United States	33	2.9k 1.1×	1.6k 1.0×	829 0.6×	1.9k 1.7×	502 0.6×	163	5.0k
Miao‐Zhen Qiu China	38	2.5k 1.0×	1.1k 0.7×	1.6k 1.2×	1.6k 1.4×	1.3k 1.6×	165	4.9k
Georg Lurje Germany	37	2.0k 0.8×	1.7k 1.1×	1.2k 0.9×	1.1k 1.0×	692 0.9×	162	4.7k
Eric X. Chen Canada	42	2.5k 1.0×	1.6k 1.0×	1.8k 1.4×	1.6k 1.4×	878 1.1×	162	5.7k
Young Suk Park South Korea	41	4.0k 1.5×	1.9k 1.2×	1.3k 1.0×	2.3k 2.0×	1.1k 1.4×	227	6.3k
Masayuki Ohue Japan	38	3.0k 1.2×	2.8k 1.7×	1.0k 0.8×	1.9k 1.6×	627 0.8×	317	5.8k
Jorge Barriuso United Kingdom	34	2.4k 0.9×	1.1k 0.7×	979 0.8×	908 0.8×	815 1.0×	137	4.0k
Lipika Goyal United States	31	2.5k 1.0×	2.3k 1.4×	1.3k 1.0×	1.4k 1.2×	854 1.1×	185	5.1k
Dirk Arnold Germany	17	2.9k 1.1×	774 0.5×	859 0.7×	921 0.8×	1.1k 1.4×	108	4.1k
Gennaro Galizia Italy	43	2.8k 1.1×	1.3k 0.8×	1.2k 0.9×	1.9k 1.7×	910 1.2×	140	5.2k

Countries citing papers authored by Amit Mahipal

Since Specialization

Citations

This map shows the geographic impact of Amit Mahipal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amit Mahipal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amit Mahipal more than expected).

Fields of papers citing papers by Amit Mahipal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amit Mahipal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amit Mahipal. The network helps show where Amit Mahipal may publish in the future.

Co-authorship network of co-authors of Amit Mahipal

This figure shows the co-authorship network connecting the top 25 collaborators of Amit Mahipal. A scholar is included among the top collaborators of Amit Mahipal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amit Mahipal. Amit Mahipal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Naing, Aung, Amit Mahipal, Milind Javle, et al.. (2025). Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 Study. PubMed. 8(1). 71–81.

Mahipal, Amit, et al.. (2024). Adoption of Total Neoadjuvant Therapy in the Treatment of Locally Advanced Rectal Cancer. Current Oncology. 31(1). 366–382. 3 indexed citations

Elshami, Mohamedraed, Jonathan J. Hue, Richard S. Hoehn, et al.. (2024). Differences in receipt of guideline-compliant care and survival for early-onset versus average-onset biliary tract cancers. 1(1). 100006–100006. 1 indexed citations

Goldman, Jonathan W., Christophe Dooms, Komal Jhaveri, et al.. (2024). Neratinib Efficacy in Patients With EGFR Exon 18-Mutant Non-Small-Cell Lung Cancer: Findings From the SUMMIT Basket Trial. Clinical Lung Cancer. 26(3). 191–200.e1. 1 indexed citations

Zemla, Tyler, Jennifer Gile, Nguyen H. Tran, et al.. (2024). Atezolizumab plus bevacizumab (A+B) as first-line systemic therapy for advanced hepatocellular carcinoma (HCC): A multi-institution analysis of patient outcomes based on Child Pugh (CP) and ALBI liver function.. Journal of Clinical Oncology. 42(16_suppl). 4099–4099. 1 indexed citations

Selfridge, J. Eva, Christopher L. Hallemeier, Krishan R. Jethwa, et al.. (2024). Circulating Tumor DNA Predicts Early Recurrence Following Locoregional Therapy for Oligometastatic Colorectal Cancer. Cancers. 16(13). 2407–2407. 1 indexed citations

Zemla, Tyler, Nguyen H. Tran, Krishan R. Jethwa, et al.. (2024). Tumor-Informed Circulating Tumor DNA for Minimal Residual Disease Detection in the Management of Colorectal Cancer. JCO Precision Oncology. 8(8). e2300127–e2300127. 6 indexed citations

Gile, Jennifer, Hani M. Babiker, Rondell P. Graham, et al.. (2024). Second-line therapies in advanced hepatocellular carcinoma following first-line atezolizumab and bevacizumab: multicenter single institution cohort experience. The Oncologist. 30(8). 1 indexed citations

Lu, Haiyan, Roger K. Moreira, Taofic Mounajjed, et al.. (2024). Neoadjuvant therapy leads to objective response in intrahepatic cholangiocarcinoma. HPB. 26(7). 938–948. 3 indexed citations

10.

Desai, Aakash, Daheui Choi, Þorvarður R. Hálfdánarson, et al.. (2024). Molecular Characterization and Therapeutic Opportunities in KRAS Wildtype Pancreatic Ductal Adenocarcinoma. Cancers. 16(10). 1861–1861. 1 indexed citations

11.

Kurniali, Peter C., et al.. (2023). Targeted Therapies in Advanced Cholangiocarcinoma. Life. 13(10). 2066–2066. 7 indexed citations

12.

Tella, Sri Harsha, Kristin C. Mara, Sakti Chakrabarti, Zhaohui Jin, & Amit Mahipal. (2023). A glimpse into the future of esophageal carcinoma in the United States: predicting the future incidence until 2040 based on the current epidemiological data. Journal of Gastrointestinal Oncology. 14(1). 1–10. 6 indexed citations

13.

Chakrabarti, Sakti, Emily Steinhagen, Ahmed A. Mohamed, et al.. (2023). P-219 Non-operative management of localized mismatch repair deficient colon cancer: A real-world perspective. Annals of Oncology. 34. S93–S93. 1 indexed citations

14.

Elshami, Mohamedraed, Richard S. Hoehn, John B. Ammori, et al.. (2023). Differences in the surgical management of early-stage hepatocellular carcinoma at minority versus non-minority-serving hospitals. Surgery. 174(5). 1201–1207. 1 indexed citations

15.

Quintanilha, Júlia C.F., Ryon P. Graf, Gerald Li, et al.. (2023). Tumor Mutational Burden in Real-World Patients With Pancreatic Cancer: Genomic Alterations and Predictive Value for Immune Checkpoint Inhibitor Effectiveness. JCO Precision Oncology. 7(7). 26–27. 31 indexed citations

16.

Grotz, Travis E., Jennifer A. Yonkus, Cornelius A. Thiels, et al.. (2022). Cytoreduction with Hyperthermic Intraperitoneal Chemoperfusion for Pancreatic Cancer with Low-Volume Peritoneal Metastasis: Results from a Prospective Pilot Study. Annals of Surgical Oncology. 30(1). 395–403. 6 indexed citations

17.

Chakrabarti, Sakti, Mandana Kamgar, & Amit Mahipal. (2020). Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm. Cancers. 12(8). 2039–2039. 53 indexed citations

18.

Münster, Pamela N., Monica Mita, Amit Mahipal, et al.. (2019). First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy. SHILAP Revista de lepidopterología. 1 indexed citations

19.

Azmi, Asfar S., Husain Yar Khan, Irfana Muqbil, et al.. (2019). Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research. 26(6). 1338–1348. 40 indexed citations

20.

Malafa, Mokenge P., Domenico Coppola, Kazim Husain, et al.. (2015). Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer. Molecular Cancer Therapeutics. 14(7). 1570–1581. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact